MISOPROSTOL 200 ug Tablet, 100-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Prostaglandin E1 Analog class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- Your pain reliever — an NSAID like ibuprofen, aspirin, or diclofenac — is effective, but it can reduce your stomach's natural defenses and raise the risk of stomach ulcers over tim...
- Why was I prescribed misoprostol along with my pain reliever?
- Unfortunately, no — and it's worth knowing this upfront. Misoprostol is designed to prevent ulcers from forming, not to relieve the everyday stomach discomfort or pain that NSAIDs...
- Will misoprostol help with the stomach pain my pain reliever causes?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Misoprostol — tap one for details:
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.8629 | $86.29 / 100 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Misoprostol 200 ug 43386-0161-01 | Lupin | 100 tablets | $0.666 | — | FDA listed | — |
| Misoprostol 200 ug 43393-0023-04 | GenBioPro, | 4 tablets | $0.700 | AB | FDA listed | — |
| Misoprostol 200 ug 43393-0024-04 | GenBioPro, | 4 tablets | $0.734 | AB | Availability likely | — |
| Misoprostol 200 ug 43393-0200-48 | GenBioPro, | 48 tablets | $0.734 | AB | Availability likely | — |
| Misoprostol 200 ug 50268-0555-60 | AvPAK | 60 tablets | $0.734 | AB | Availability likely | — |
| misoprostol 200 ug 59762-5008-01 | Mylan | 60 tablets | $0.734 | AB | Availability likely | — |
| Misoprostol 200 ug 60687-0746-01 | American | 100 tablets | $0.734 | AB | Availability likely | — |
| Misoprostol 200 ug 70954-0444-10 | ANI | 60 tablets | $0.734 | AB | Availability likely | — |
| Cytotec 200 ug 00025-1461-31 | Pfizer | 100 tablets | — | AB | FDA listed | — |
| Misoprostol 200 ug 40032-0161-01 | Novel | 100 tablets | — | — | FDA listed | — |
| Misoprostol 200 ugthis 42571-0254-01 | Micro | 100 tablets | — | AB | Discontinued | — |
| Misoprostol 200 ug 54348-0148-00 | PharmPak, | 1 tablet | — | — | FDA listed | — |
| Misoprostol 200 ug 55154-2145-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
| misoprostol 200 ug 67296-1936-01 | Redpharm | 10 tablets | — | AB | FDA listed | — |
| Misoprostol 200 ug 68071-4843-03 | NuCare | 3 tablets | — | — | FDA listed | — |
| Misoprostol 200 ug 72789-0300-04 | PD-Rx | 4 tablets | — | AB | FDA listed | — |
| Misoprostol 200 ug 82804-0037-10 | Proficient | 10 tablets | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 42571-0254-01 You're viewing this | 100 TABLET in 1 BOTTLE (42571-254-01) | 2023-01-01 | Discontinued by firm |
| 42571-0254-60 | 60 TABLET in 1 BOTTLE (42571-254-60) | 2023-01-01 | Discontinued by firm |
You're viewing the largest of 2 pack sizes for this product.
Pack size FAQ
What quantity is in NDC 42571-0254-01?
What is the difference between NDC 42571-0254-01 and NDC 42571-0254-60?
What NDC number is used to bill for this package of MISOPROSTOL 200 ug Tablet?
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
What does the discontinued status mean for this NDC?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Does this product come in other package sizes?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🚨 Boxed Warning ▾
WARNINGS MISOPROSTOL ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE BIRTH DEFECTS, ABORTION, PREMATURE BIRTH OR UTERINE RUPTURE. UTERINE RUPTURE HAS BEEN REPORTED WHEN MISOPROSTOL WAS ADMINISTERED IN PREGNANT WOMEN TO INDUCE LABOR OR TO INDUCE ABORTION. THE RISK OF UTERINE RUPTURE INCREASES WITH ADVANCING GESTATIONAL AGES AND WITH PRIOR UTERINE SURGERY, INCLUDING CESAREAN DELIVERY (see also PRECAUTIONS and LABOR AND DELIVERY ).
MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS. Misoprostol should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration.
In such patients, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy. is capable of complying with effective contraceptive measures. has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake. will begin misoprostol only on the second or third day of the next normal menstrual period.
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Misoprostol tablets are indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol tablets has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol tablets should be taken for the duration of NSAID therapy.
Misoprostol tablets has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION The recommended adult oral dose of misoprostol for reducing the risk of NSAID-induced gastric ulcers is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used. (See Clinical Pharmacology: Clinical studies . ) Misoprostol should be taken for the duration of NSAID therapy as prescribed by the physician.
Misoprostol should be taken with a meal, and the last dose of the day should be at bedtime. Renal impairment: Adjustment of the dosing schedule in renally impaired patients is not routinely needed, but dosage can be reduced if the 200-mcg dose is not tolerated. (See Clinical Pharmacology . )
⛔ Contraindications ▾
CONTRAINDICATIONS See boxed WARNINGS . Misoprostol tablets should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs). Misoprostol tablets should not be taken by anyone with a history of allergy to prostaglandins.
⚠️ Warnings ▾
WARNINGS See boxed WARNINGS . For hospital use only if misoprostol were to be used for cervical ripening, induction of labor, or for the treatment of serious post-partum hemorrhage, which are outside of the approved indication.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following have been reported as adverse events in subjects receiving misoprostol: Gastrointestinal: In subjects receiving misoprostol 400 or 800 mcg daily in clinical trials, the most frequent gastrointestinal adverse events were diarrhea and abdominal pain. The incidence of diarrhea at 800 mcg in controlled trials in patients on NSAIDs ranged from 14 to 40% and in all studies (over 5,000 patients) averaged 13%. Abdominal pain occurred in 13 to 20% of patients in NSAID trials and about 7% in all studies, but there was no consistent difference from placebo.
Diarrhea was dose related and usually developed early in the course of therapy (after 13 days), usually was self-limiting (often resolving after 8 days), but sometimes required discontinuation of misoprostol (2% of the patients). Rare instances of profound diarrhea leading to severe dehydration have been reported. Patients with an underlying condition such as inflammatory bowel disease, or those in whom dehydration, were it to occur, would be dangerous, should be monitored carefully if misoprostol is prescribed.
The incidence of diarrhea can be minimized by administering after meals and at bedtime, and by avoiding coadministration of misoprostol with magnesium-containing antacids. Gynecological: Women who received misoprostol during clinical trials reported the following gynecological disorders: spotting (0.7%), cramps (0.6%), hypermenorrhea (0.5%), menstrual disorder (0.3%) and dysmenorrhea (0.1%). Postmenopausal vaginal bleeding may be related to misoprostol administration.
If it occurs, diagnostic workup should be undertaken to rule out gynecological pathology. (See boxed WARNINGS. ) Elderly: There were no significant differences in the safety profile of misoprostol in approximately 500 ulcer patients who were 65 years of age or older compared with younger patients. Additional adverse events which were reported are categorized as follows: Incidence greater than 1%: In clinical trials, the following adverse reactions were reported by more than 1% of the subjects receiving misoprostol and may be causally related to the drug: nausea (3.2%), flatulence (2.9%), headache (2.4%), dyspepsia (2%), vomiting (1.3%), and constipation (1.1%).
However, there were no significant differences between the incidences of these events for misoprostol and placebo. Causal relationship unknown: The following adverse events were infrequently reported. Causal relationships between misoprostol and these events have not been established but cannot be excluded: Body as a whole: aches/pains, asthenia, fatigue, fever, chills, rigors, weight changes.
Skin: rash, dermatitis, alopecia, pallor, breast pain. Special senses: abnormal taste, abnormal vision, conjunctivitis, deafness, tinnitus, earache. Respiratory: upper respiratory tract infection, bronchitis, bronchospasm, dyspnea, pneumonia, epistaxis.
Cardiovascular: chest pain, edema, diaphoresis, hypotension, hypertension, arrhythmia, phlebitis, increased cardiac enzymes, syncope, myocardial infarction (some fatal), thromboembolic events (e.g., pulmonary embolism, arterial thrombosis, and CVA). Gastrointestinal: GI bleeding, GI inflammation/infection, rectal disorder, abnormal hepatobiliary function, gingivitis, reflux, dysphagia, amylase increase. Hypersensitivity: anaphylactic reaction Metabolic: glycosuria, gout, increased nitrogen, increased alkaline phosphatase.
Genitourinary: polyuria, dysuria, hematuria, urinary tract infection. Nervous system/Psychiatric: anxiety, change in appetite, depression, drowsiness, dizziness, thirst, impotence, loss of libido, sweating increase, neuropathy, neurosis, confusion. Musculoskeletal: arthralgia, myalgia, muscle cramps, stiffness, back pain.
Blood/Coagulation: anemia, abnormal differential, thrombocytopenia, purpura, ESR increased. To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs USA, Inc. at 1-855-839-8195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🆘 Overdosage ▾
OVERDOSAGE The toxic dose of misoprostol in humans has not been determined. Cumulative total daily doses of 1600 mcg have been tolerated, with only symptoms of gastrointestinal discomfort being reported. In animals, the acute toxic effects are diarrhea, gastrointestinal lesions, focal cardiac necrosis, hepatic necrosis, renal tubular necrosis, testicular atrophy, respiratory difficulties, and depression of the central nervous system.
Clinical signs that may indicate an overdose are sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, or bradycardia. Symptoms should be treated with supportive therapy. It is not known if misoprostol acid is dialyzable.
However, because misoprostol is metabolized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for overdosage.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Pharmacokinetics: Misoprostol is extensively absorbed, and undergoes rapid de-esterification to its free acid, which is responsible for its clinical activity and, unlike the parent compound, is detectable in plasma. The alpha side chain undergoes beta oxidation and the beta side chain undergoes omega oxidation followed by reduction of the ketone to give prostaglandin F analogs. In normal volunteers, misoprostol is rapidly absorbed after oral administration with a T max of misoprostol acid of 12 ± 3 minutes and a terminal half-life of 20 to 40 minutes.
There is high variability of plasma levels of misoprostol acid between and within studies but mean values after single doses show a linear relationship with dose over the range of 200 to 400 mcg. No accumulation of misoprostol acid was noted in multiple dose studies; plasma steady state was achieved within two days. Maximum plasma concentrations of misoprostol acid are diminished when the dose is taken with food and total availability of misoprostol acid is reduced by use of concomitant antacid.
Clinical trials were conducted with concomitant antacid, however, so this effect does not appear to be clinically important. Mean ± SD C max (pg/mL) AUC(0 to 4) (pg·hr/mL) T max (min) Fasting 811 ± 317 417 ± 135 14 ± 8 With Antacid 689 ± 315 349 ± 108* 20 ± 14 With High Fat Breakfast 303 ± 176* 373 ± 111 64 ± 79* * Comparisons with fasting results statistically significant, p<0.05. After oral administration of radiolabeled misoprostol, about 80% of detected radioactivity appears in urine.
Pharmacokinetic studies in patients with varying degrees of renal impairment showed an approximate doubling of T 1/2 , C max , and AUC compared to normals, but no clear correlation between the degree of impairment and AUC. In subjects over 64 years of age, the AUC for misoprostol acid is increased. No routine dosage adjustment is recommended in older patients or patients with renal impairment, but dosage may need to be reduced if the usual dose is not tolerated.
Drug interaction studies between misoprostol and several nonsteroidal anti-inflammatory drugs showed no effect on the kinetics of ibuprofen or diclofenac, and a 20% decrease in aspirin AUC, not thought to be clinically significant. Pharmacokinetic studies also showed a lack of drug interaction with antipyrine and propranolol when these drugs were given with misoprostol. Misoprostol given for 1 week had no effect on the steady state pharmacokinetics of diazepam when the two drugs were administered 2 hours apart.
The serum protein binding of misoprostol acid is less than 90% and is concentration- independent in the therapeutic range. After a single oral dose of misoprostol to nursing mothers, misoprostol acid was excreted in breast milk. The maximum concentration of misoprostol acid in expressed breast milk was achieved within 1 hour after dosing and was 7.6 pg/mL (CV 37%) and 20.9 pg/mL (CV 62%) after single 200 mcg and 600 mcg misoprostol administration, respectively.
The misoprostol acid concentrations in breast milk declined to < 1 pg/mL at 5 hours post-dose. Pharmacodynamics: Misoprostol has both antisecretory (inhibiting gastric acid secretion) and (in animals) mucosal protective properties. NSAIDs inhibit prostaglandin synthesis, and a deficiency of prostaglandins within the gastric mucosa may lead to diminishing bicarbonate and mucus secretion and may contribute to the mucosal damage caused by these agents.
Misoprostol can increase bicarbonate and mucus production, but in man this has been shown at doses 200 mcg and above that are also antisecretory. It is therefore not possible to tell whether the ability of misoprostol to reduce the risk of gastric ulcer is the result of its antisecretory effect, its mucosal protective effect, or both. In vitro studies on canine parietal cells using tritiated misoprostol acid as the ligand have led to the identification and characterization of specific prostaglandin receptors.
Recept…
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Misoprostol 100 mcg tablets are white to off white, round, biconvex, uncoated tablet debossed with “C” and “41” on one side and plain on the other side; supplied as: Bottles of 60 NDC 42571-253-60 Bottles of 120 NDC 42571-253-12 Misoprostol 200 mcg tablets are white to off white, round, biconvex, uncoated tablet debossed with “C” and “40” on one side and break line on the other side; supplied as: Bottles of 60 NDC 42571-254-60 Bottles of 100 NDC 42571-254-01 Store at or below 25°C (77°F), in a dry area.
The brands listed are trademarks of their respective owners and are not trademarks of Micro Labs Limited. The makers of these brands are not affiliated with and do not endorse Micro Labs or its products. Rx Only Manufactured by: Micro Labs Limited Goa- 403 722, INDIA.
Manufactured for: Micro Labs USA, Inc. Somerset, NJ 08873 Rev. 12/2022
📋 Description ▾
DESCRIPTION Misoprostol oral tablets contain either 100 mcg or 200 mcg of misoprostol, a synthetic prostaglandin E 1 analog. Misoprostol USP contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by (±): Misoprostol USP is a clear, colorless or light yellow viscous liquid. Very slightly soluble in water.
Inactive ingredients of tablets are colloidal silicon dioxide, hydrogenated castor oil, hypromellose, microcrystalline cellulose, and sodium starch glycolate. misotab-str.jpg